## Review setup
- **Input scope** Abstract only
- **Assessment boundary** The protocol description and its stated rationale, as presented in the abstract
- **Shared manuscript claim summary** The authors describe a protocol that integrates Thioflavin T (ThT) fluorescence aggregation assays with GROMACS-derived conformational ensembles to correlate experimentally determined aggregation propensities of peptides with their local structural features, with the aim of uncovering structural rules governing how local elements modulate amyloid motif aggregation in intrinsically disordered proteins.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or results are provided
- **Missing materials affecting confidence** Full methods, experimental data, simulation parameters, validation statistics, and any comparative analyses; the cited prior work (Chen, Nat Commun 10:2493, 2019) is referenced but not summarized in sufficient detail

## Reviewer
- **Overall assessment** The abstract presents a conceptually interesting protocol that combines experimental aggregation assays with molecular dynamics simulations to address a mechanistically important question in amyloid biology. However, the abstract provides insufficient detail to evaluate the protocol's novelty, technical validity, or generalizability. The central claim that local structural elements can shield amyloid motifs is plausible and supported by prior work, but the current abstract does not establish the protocol's effectiveness or its broader applicability beyond the specific tau example. The writing is clear but lacks specificity regarding the integration of experiment and simulation.
- **Who would be interested in the results, and why** Researchers studying protein aggregation in neurodegenerative diseases, particularly those focused on intrinsically disordered proteins and amyloid motif biology. Computational biophysicists interested in simulation-experiment integration for aggregation prediction would also find the protocol relevant. The methods-oriented nature of the target journal suggests a practical audience seeking reproducible protocols.
- **Major strengths** The abstract addresses a significant gap in understanding how local structural elements in IDPs modulate amyloid aggregation. The proposed integration of ThT assays with GROMACS simulations is a reasonable and potentially powerful approach. The focus on tau, a disease-relevant protein, enhances translational relevance.
- **Major Concerns** The abstract lacks quantitative evidence or validation of the protocol's predictive power. The relationship between simulation-derived conformational ensembles and experimentally measured aggregation propensities is asserted but not demonstrated. The generalizability claim is not supported by the limited scope described.
- **Minor Comments** The abstract would benefit from specifying the peptide sequences used, the simulation timescales, and the statistical methods for correlating simulation and experiment. The phrase "metastable beta-hairpin-like structures" is used without defining the structural criteria applied.
- **Technical failings that need to be addressed before the case is established** The abstract does not provide any data showing that the protocol successfully correlates simulation and experiment. Without such evidence, the protocol's utility cannot be assessed.
- **Assessment against Nature-style criteria** Originality: Moderate, as the concept of local structure modulating aggregation is not entirely new, but the specific integration approach may offer novelty. Scientific importance: High, given the disease relevance and mechanistic questions addressed. Interdisciplinary readership: Moderate, as the work bridges experimental biophysics and computational simulation, but the abstract is too specialized for broad appeal. Technical soundness: Not assessable from the abstract alone, as no technical details or validation are provided. Readability for nonspecialists: The abstract is accessible but assumes familiarity with amyloid biology and simulation methods.
- **Recommendation posture** Currently not established from the provided evidence. The abstract describes a protocol but does not provide sufficient evidence to evaluate its effectiveness or generalizability. A full manuscript with validation data would be required to assess the claims.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Evidence sufficiency
- **Claim pointer** The protocol "correlates experimentally determined aggregation propensities for peptides measured by the Thioflavin T (ThT) fluorescence aggregation assay with their conformational ensembles derived from Groningen machine chemical simulations (GROMACS)."
- **Evidence pointer** Abstract text; location not provided
- **Concern** The abstract asserts a correlation between ThT-measured aggregation propensities and GROMACS-derived conformational ensembles, but no data, statistical measures, or representative results are presented to support this correlation. The nature of the correlation (e.g., linear, threshold-based, qualitative) is unspecified.
- **Why it matters** Without evidence of a successful correlation, the protocol's central utility is unsubstantiated. Readers cannot determine whether the approach yields meaningful predictions or whether the simulation and experiment are actually integrated in a quantitative manner.
- **Resolution test** Provide representative data showing the correlation, including statistical metrics (e.g., R-squared, p-values) and a description of the analysis method. If the correlation is qualitative, state this explicitly and provide examples.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Generalizability
- **Claim pointer** "We anticipate that our general protocol will help identify key interactions in local structures that engage amyloid-forming motifs in IDPs which influence aggregation behavior."
- **Evidence pointer** Abstract text; location not provided
- **Concern** The claim of generalizability is made without evidence that the protocol has been tested on multiple IDPs or amyloid motifs beyond the tau example. The abstract does not specify whether the protocol is applicable to other proteins or whether it requires case-specific adjustments.
- **Why it matters** The stated anticipation of general utility is a key selling point for a methods paper. If the protocol is only validated for tau, the generalizability claim is overreaching and could mislead potential users.
- **Resolution test** Describe validation on at least one additional IDP or provide a clear rationale for why the protocol is transferable. Alternatively, temper the claim to reflect the current scope.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Technical detail
- **Claim pointer** "local structural elements can modify the aggregation propensity of amyloid motifs in the intrinsically disordered microtubule-associated protein tau by adopting metastable beta-hairpin-like structures that shield the amyloid motif"
- **Evidence pointer** Abstract text; location not provided
- **Concern** The abstract references prior work (Chen, Nat Commun 10:2493, 2019) to support the beta-hairpin shielding mechanism, but does not explain how the current protocol builds on or extends this finding. The structural criteria for identifying "metastable beta-hairpin-like structures" in simulations are not defined.
- **Why it matters** For a methods protocol, clarity on structural definitions and the novelty relative to prior work is essential. Without this, readers cannot assess the protocol's added value or reproduce the analysis.
- **Resolution test** Specify the structural criteria used to define beta-hairpin-like conformations in the simulation analysis and explicitly state how the protocol differs from or improves upon the cited prior work.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Protocol scope
- **Evidence pointer** Abstract text; location not provided
- **Issue** The abstract does not specify the peptide sequences or the range of aggregation propensities tested, which limits the reader's ability to gauge the protocol's applicability.
- **Required correction** Include a brief description of the peptide set used, including sequence length and mutation variants, in the abstract or indicate that full details are in the methods.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Simulation parameters
- **Evidence pointer** Abstract text; location not provided
- **Issue** The abstract mentions GROMACS simulations but provides no information on force field, simulation length, temperature, or replica sampling, which are critical for reproducibility.
- **Required correction** Add a sentence summarizing key simulation parameters or state that they are fully detailed in the methods section.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Terminology
- **Affected element** "Groningen machine chemical simulations"
- **Evidence pointer** Abstract text; location not provided
- **Issue** The term "Groningen machine chemical simulations" is an unusual phrasing for GROMACS, which is typically described as a molecular dynamics simulation package. This may confuse readers.
- **Required correction** Use the standard terminology "GROMACS molecular dynamics simulations" for clarity.

## Risk / unsupported claims
- The claim that the protocol "correlates" experimental and simulation data is unsupported, as no correlation results are presented.
- The claim of generalizability to other IDPs is unsupported, as only tau is mentioned.
- The mechanistic claim regarding beta-hairpin shielding is referenced to prior work but not substantiated within this abstract.
- The protocol's effectiveness in "help[ing] identify key interactions" is speculative and not demonstrated.